Why the study?
Heart failure with mildly reduced ejection fraction has overlapping pathophysiology with both reduced and preserved ejection fraction, complicating standard diagnostic, follow-up, and management recommendations.
Answers are grounded in this paper and cite their sources.
This review highlights that SGLT2 inhibitors are becoming the standard of care for heart failure with mildly reduced ejection fraction, a group where traditional therapies only have a class IIb recommendation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Aristizábal-Colorado et al. (2023) conducted a review in Heart failure with mildly reduced ejection fraction. Heart failure therapies (SGLT2 inhibitors, beta-blockers, ACEi/ARBs, MRAs) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: